Navigation Links
Study holds promise for new way to fight HIV

There has always been a quest regarding the treatment of AIDS/HIV infection that has been haunting the world. Despite the initiation of a global research, AIDS still remains a puzzle to be tackled effectively. Approximately five percent of patients with HIV, or human immunodeficiency virus, do not develop AIDS, or do so very slowly.//

Past research suggested that such patients maintain higher levels of an enzyme in white blood cells called APOBEC-3G (A3G), and the new study confirmed it in the first experiments on human cells. These patients remain healthy even after years of infection with HIV despite receiving no treatment. These results have confirmed the presence of an innate defense system present in such subjects.

It is believed that A3G "edits," or introduces changes in, the HIV genetic code every time the virus copies itself. By doing so, A3G corrupts the HIV gene code and prevents the virus from reproducing. However, the HIV virus overcomes this difficulty with the help of viral infectivity factor (Vif) that directs the body to destroy A3G. HIV is then free to overwhelm the immune system, leaving patients vulnerable to AIDS infections.

It has been hypothesized that people suffering from the effects of HIV infection do not make or produce sufficient amounts of the A3G protein to combat Vif and shut it down. Therefore protecting whatever amount of A3G that people do have from Vif represents a new way to attack HIV.

To confirm that A3G offers strong protection against HIV, researchers in the current study measured A3G levels in the immune cells of six people not infected with HIV and in 25 patients with the virus. It was found that higher levels of A3G closely corresponded to lower HIV viral levels.

Furthermore, the team determined that nonprogressors have the most A3G editing enzyme, followed by those not infected with HIV and lastly by those progressing toward full-blown AIDS.

The study has t he potential to frame a new prognostic marker for AIDS by enabling the measurement of A3G levels in HIV-infected patients. It will also clarify a previously unrecognized mechanism that underlies slower disease progression in long-term nonprogressors. Lastly, the data suggest that protecting A3G from viral attack may be an important new way to treat AIDS and other viral infections.
'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... ... April 25, 2017 , ... As Spring reignites ... defects research related to Zika virus during pregnancy, as well as other prenatal ... important science. , The Teratology Society is an international and ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the ... or chronic problems, I focus on preventative care with all my patients to alleviate possible ... questions, always feel free to contact my office and my trained staff will assist you ...
(Date:4/25/2017)... ... 25, 2017 , ... There is no better place in South Florida to ... in the May issue of Consumer Reports focused on heart health. , The ... during and after coronary bypass and aortic valve replacement procedures. , Consumer Reports ...
(Date:4/24/2017)... ... April 24, 2017 , ... Emmanuel College is introducing ... advance their careers. Beginning in the fall of 2017, Emmanuel’s program will allow registered ... few as 16 months and for as little as $14,528. These changes will enable ...
(Date:4/24/2017)... ... ... The Santana Telehealth Project was honored with the 2017 ATA Humanitarian Award. The ... conference, on April 23 in Orlando, FL. , “I am proud that ATA is ... poor and underserved in other parts of the world,” said Jonathan Linkous, CEO of ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
(Date:4/19/2017)... , April 19, 2017 Global Prostate ... report on the prostate cancer therapeutics market analyzes ... market. Increasing prevalence of prostate cancer, launch of ... the development of new drugs & therapeutic biological ... drug due to lesser side effects are some ...
Breaking Medicine Technology: